摘要:
The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.
摘要:
The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.
摘要:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
摘要:
The present invention relates to novel octapeptide compounds of general formula (I), R-AA1-cyclo(AA2-Tyr3-D-Trp4-AA5-Val6-Cys7)-Thr8-NH2 (I) As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.
摘要:
The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
摘要:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
摘要:
The invention relates to a long-acting solid formulation for parenteral administration, comprising a) triptorelin acetate and b) one or more excipients comprising a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic acid and/or glycolic acid, said formulation containing 10 to 99% of triptorelin acetate by weight with relation to the total weight of the formulation. Said formulation is obtained by means of a method comprising the fusion of a mixture of triptorelin acetate and the excipient(s) on the fusion/extrusion of the triptorelin acetate with the excipient(s), said formulation being embodied such as to release the triptorelin acetate over a duration of at least one week, once administered parenterally to a patient.
摘要:
The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
摘要:
The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogs thereof and the manufacturing process of such pharmaceutical compositions.
摘要:
The invention concerns a device for injecting a solid medicine (10) comprising a body (2) inside which moves along a general forward moving axis (X-X) a bevelled (34) needle (4) wherein is introduced the medicine (10), said injection device (1) further comprising retaining means for preventing the medicine from falling (10) prior to being injected. The invention is characterized in that the medicine (10) is retained through an elastic deformation imparted to the needle (4) by the retaining means or by an elastic deformation of the retaining means themselves, or still by the combined flexibility of those two means.